Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
25 hedge funds and large institutions have $464M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 79 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
81% more capital invested
Capital invested by funds: $257M → $464M (+$207M)
71% less funds holding
Funds holding: 85 → 25 (-60)
75% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$239M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
+$166M |
| 3 |
SGA
SB Global Advisers
London,
United Kingdom
|
+$108M |
| 4 |
TAA
TB Alternative Assets
Grand Cayman,
Cayman Islands
|
+$18.5M |
| 5 |
PA
Perceptive Advisors
New York
|
+$8.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.6M |
| 2 |
CM
Cohanzick Management
Pleasantville,
New York
|
-$13.6M |
| 3 |
RA
RiverPark Advisors
New York
|
-$13M |
| 4 |
Millennium Management
New York
|
-$12M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$11.9M |
PEAR Hedge Fund Activity: Q4 2021 in Review
25 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q4 2021, worth a combined $464M — up 81% from $257M a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of PEAR and 20 opened new positions — a net loss of 59 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Temasek Holdings, opening a new position worth an estimated $239M. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.6M sold.
- 25 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q4 2021, down from 85 in Q3 2021.
- Funds reported $464M of Pear Therapeutics, Inc. Class A Common Stock stock for Q4 2021, up 81% quarter-over-quarter.
- 20 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q4 2021 and 79 closed out, a net change of -59 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q4 2021 was Temasek Holdings, an estimated $239M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q4 2021 was Citadel Advisors, an estimated $19.6M sold.
Based on aggregated 13F filings for Q4 2021.